Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase IV commitment to study cardio risk is part of saxagliptin's approval, but the partners are also looking for data to support a claim of cardioprotective effect.